A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


April 25, 2012

Report Outlines HIV Cure Research, Important Gaps

by Tim Horn

Three HIV/AIDS activist groups convened a meeting in March with researchers and representatives of the U.S. Food and Drug Administration (FDA) to describe the current state of cure research and identify barriers to moving such research forward swiftly and smoothly. The proceedings of this meeting, which took place immediately before the 19th Conference on Retroviruses and Opportunistic Infections (CROI) that began on March 5 in Seattle, are now available in a report online.

“A cure for HIV will be essential to ending the AIDS pandemic, but science that is focused directly on a cure is still in early stages and will likely require the support of multiple stakeholders to proceed at the fastest pace,” reads the executive summary of the report, authored by David Evans, Kevin Fisher, Jeff Taylor and Siegfried Schwarze.

In the past four years, the report notes, there have been signs of increasing scientific momentum and funding directed toward curing HIV infection.

The remarkable case of “Berlin Patient” Timothy Brown—a man who all signs suggest has been cured of HIV—has catalyzed and expanded what was once a small and somewhat fragmented effort to understand how HIV persists despite effective antiretroviral (ARV) therapy and to explore mechanisms to eliminate the hidden pool of virus in people on ARV treatment (a sterilizing cure) or to enable the immune system to control HIV without the need for ARVs (a functional cure).

This momentum, the activists write, has been greatly enhanced by the NIH-funded Martin Delaney Collaboratory projects, partnerships between academia and industry focused on the possibility of discovering and developing a safe, effective, feasible and scalable HIV cure.

Among recent signs of progress, researchers have contributed new insights into where and why HIV persists despite potent ARV therapy. In addition, the first controlled clinical trials of drugs to activate cells harboring archived HIV, such as histone deacetylase (HDAC) inhibitors, are yielding promising signals, and other types of treatments designed to teach the immune system to either clear or control the virus on its own have been initiated.

But central questions remain, the report stresses.

For example, it is still not clear what types of cells and anatomical compartments harbor HIV, nor is it understood which methods work best for measuring the latent virus in these reservoirs. Knowledge regarding how HIV is able to replenish these reservoirs, even when ARVs with “maximally suppressive” effects on viral load are being used consistently and correctly, is also needed. Actually, it’s not entirely clear if modern ARV therapy is, in fact, fully suppressing HIV replication. And does the immune system play a role in HIV persistence? In addition, what are the forms of immunologic HIV control that can potentially be enhanced without major safety issues?

Finally, the report asks, what are “reasonable” risks for the people living with HIV who will be participating in early—and potentially dangerous—studies, and how can these individuals be best protected?

To address these questions, members of the AIDS Treatment Activists Coalition (ATAC), the Treatment Action Group (TAG) and Project Inform sat down with several industry and academic researchers on March 4 in Seattle, who described their current projects, outlined the obstacles and facilitators to cure research and offered suggestions for the kinds of activities that community advocates might undertake to overcome current obstacles.

Highlights include: an overview of AIDS Clinical Trials Group (ACTG) clinical trial development by Dan Kuritzkes, MD; laboratory testing for new compounds, including work being conducted by Romas Geleziunas, PhD, at Gilead Sciences; the prospects of gene therapy, notably ongoing zinc finger nuclease work at Sangamo Biosciences, discussed by Dale Ando, MD; stem cell research after the Berlin Patient, highlighted by John Zaia, MD, who underscored the importance of not overselling this approach; and work focusing on the enhancement of immune responses, reviewed by Pablo Tebas, MD.

The post-meeting report, issued in April, provides a brief synopsis of each presentation, followed by an outline of areas identified by the workshop speakers and participants for further exploration, development and incorporation into a cure advocacy agenda.

“The prevailing view of all the speakers was that we must not raise premature and unrealistic hopes of a cure for HIV either in people who volunteer their bodies for cure research, or in the wider community of people with HIV and their allies,” the authors write. “Critical early steps have been identified, but we need many more successes in analytics, basic science and translational research—in both animals and people—before the cure will be within our grasp.”

Search: cure, research, science, advocacy, activism, treatment action group, tag, aids treatment activists coalition, atac, project inform, gene therapy, immune-based therapy, stem cells, therapeutic vaccines

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (14 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.